Abstract | OBJECTIVES: BACKGROUND: METHODS: A randomized, double-blind crossover trial of nadolol, verapamil and placebo, administered for periods of 4 weeks each, was performed in 18 patients with mild or moderately symptomatic hypertrophic cardiomyopathy (10 men, 8 women; mean age +/- SD 39 +/- 17 years). A detailed symptom assessment, bicycle exercise testing, echocardiography and Holter monitoring were performed in each period. RESULTS: Two patients withdrew from the study owing to symptomatic sinus bradycardia during nadolol therapy. Neither drug improved maximal oxygen consumption (placebo 26 +/- 8, verapamil 23 +/- 6, nadolol 21 +/- 7 ml/kg per min; p = 0.1). Peak exercise work load was reduced by > or = 10 W in 13 patients (81%) during nadolol therapy and in 4 patients (25%) during verapamil therapy (p = 0.005, nadolol vs. verapamil). Despite the effects on exercise capacity, 13 patients (81%) preferred drug treatment (8 verapamil, 5 nadolol) over placebo (p = 0.001). Verapamil improved reported performance at work compared with nadolol (p = 0.01) and tended to improve other measures of health-related behavior and symptoms compared with nadolol and placebo. CONCLUSIONS:
|
Authors | D M Gilligan, W L Chan, J Joshi, P Clarke, A Fletcher, S Krikler, C M Oakley |
Journal | Journal of the American College of Cardiology
(J Am Coll Cardiol)
Vol. 21
Issue 7
Pg. 1672-9
(Jun 1993)
ISSN: 0735-1097 [Print] United States |
PMID | 8496536
(Publication Type: Clinical Trial, Journal Article, Randomized Controlled Trial, Research Support, Non-U.S. Gov't)
|
Chemical References |
|
Topics |
- Adolescent
- Adult
- Aged
- Cardiomyopathy, Hypertrophic
(drug therapy, physiopathology)
- Double-Blind Method
- Electrocardiography
- Exercise Tolerance
- Female
- Humans
- Male
- Middle Aged
- Nadolol
(adverse effects, therapeutic use)
- Patient Satisfaction
- Quality of Life
- Treatment Outcome
- Verapamil
(adverse effects, therapeutic use)
|